The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
National Cancer Institute. SEER Cancer Statistics Review 1975-2009: myelodysplastic syndromes (MDS) chronic myeloproliferative disorders (CMD) and chronic myelomonocytic leukemia (CMML). 2010. Available at: http://seer.cancer.gov/csr/1975_2007/results_merged/sect_30_mds.pdf. Accessed April 2013.
National Cancer Institute. SEER Cancer Statistics Review 1975-2009: myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD), and chronic myelomonocytic leukemia (CMML). 2010. Available at: http://seer.cancer.gov/csr/1975_2007/results_merged/sect_30_mds.pdf. Accessed April 2013.
)| false
VardimanJWThieleJArberDA. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937–951.
VardimanJWThieleJArberDA. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937–951.
)| false
BrunningRBennettJFlandrinG. Myelodysplastic syndromes. In: JaffeEHarrisNSteinH eds. WHO Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:61–73.
BrunningRBennettJFlandrinG. Myelodysplastic syndromes. In: JaffeEHarrisNSteinH, eds. WHO Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:61–73.
)| false
HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:3835–3849.
HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:3835–3849.
)| false
GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood 1998;91:1100]. Blood1997;89:2079–2088.
GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood 1998;91:1100]. Blood1997;89:2079–2088.
)| false
VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasms. In: SwerdlowSHCampoEHarrisNL eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC; 2008:75–86.
VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasms. In: SwerdlowSHCampoEHarrisNL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC; 2008:75–86.
)| false
GreenbergPAndersonJde WitteT. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol2000;18:3447–3452.
GreenbergPAndersonJde WitteT. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol2000;18:3447–3452.
)| false
ArberDABrunningRDOraziA. Acute myeloid leukaemia with myelodysplasia-related changes. In Chapter 6: Acute myeloid leukemia and related precursor neoplasms. In: SwerdlowSCampoEHarrisNL eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008:124–126.
ArberDABrunningRDOraziA. Acute myeloid leukaemia with myelodysplasia-related changes. In Chapter 6: Acute myeloid leukemia and related precursor neoplasms. In: SwerdlowSCampoEHarrisNL, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.Lyon, France: IARC Press; 2008:124–126.
)| false
GermingUGattermannNStruppC. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res2000;24:983–992.
GermingUGattermannNStruppC. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res2000;24:983–992.
)| false
GermingUStruppCKuendgenA. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol2006;132:162–167.
GermingUStruppCKuendgenA. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol2006;132:162–167.
)| false
GermingUStruppCKuendgenA. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica2006;91:1596–1604.
GermingUStruppCKuendgenA. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica2006;91:1596–1604.
)| false
MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:7594–7603.
MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:7594–7603.
)| false
Muller-BerndorffHHaasPSKunzmannR. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol2006;85:502–513.
Muller-BerndorffHHaasPSKunzmannR. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol2006;85:502–513.
)| false
ValentPHornyHPBennettJM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res2007;31:727–736.
ValentPHornyHPBennettJM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res2007;31:727–736.
)| false
JafarzadehAPoorgholamiMIzadiN. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med2010;33:E271–279.
JafarzadehAPoorgholamiMIzadiN. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med2010;33:E271–279.
)| false
DunnDETanawattanacharoenPBoccuniP. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med1999;131:401–408.
DunnDETanawattanacharoenPBoccuniP. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med1999;131:401–408.
)| false
SaunthararajahYNakamuraRNamJM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood2002;100:1570–1574.
SaunthararajahYNakamuraRNamJM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood2002;100:1570–1574.
)| false
BorowitzMJCraigFEDigiuseppeJA. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom2010;78:211–230.
BorowitzMJCraigFEDigiuseppeJA. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom2010;78:211–230.
)| false
TakedaJMiyataTKawagoeK. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell1993;73:703–711.
TakedaJMiyataTKawagoeK. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell1993;73:703–711.
)| false
BattiwallaMHepgurMPanD. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. Cytometry B Clin Cytom2010;78:348–356.
BattiwallaMHepgurMPanD. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. Cytometry B Clin Cytom2010;78:348–356.
)| false
KussickSJFrommJRRossiniA. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol2005;124:170–181.
KussickSJFrommJRRossiniA. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol2005;124:170–181.
)| false
van de LoosdrechtAAAlhanCBeneMC. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica2009;94:1124–1134.
van de LoosdrechtAAAlhanCBeneMC. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica2009;94:1124–1134.
)| false
WestersTMIrelandRKernW. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia2012;26:1730–1741.
WestersTMIrelandRKernW. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia2012;26:1730–1741.
)| false
WoodBLArrozMBarnettD. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom2007;72(Suppl 1):S14–22.
WoodBLArrozMBarnettD. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom2007;72(Suppl 1):S14–22.
)| false
Della PortaMGPiconeCPascuttoC. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica2012;97:1209–1217.
Della PortaMGPiconeCPascuttoC. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica2012;97:1209–1217.
)| false
ChanWCFoucarKMoriceWGCatovskyD. T-cell large granular lymphocytic leukemia. In: SwerdlowSHCampoEHarrisNL eds. WHO classification of tumours of haematopoietic and lymphoid tissues4th ed.Lyon, France: IARC; 2008:272–273.
ChanWCFoucarKMoriceWGCatovskyD. T-cell large granular lymphocytic leukemia. In: SwerdlowSHCampoEHarrisNL, eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed.Lyon, France: IARC; 2008:272–273.
)| false
DuHYPumboEIvanovichJ. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood2009;113:309–316.
DuHYPumboEIvanovichJ. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood2009;113:309–316.
)| false
VulliamyTJMarroneAKnightSW. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood2006;107:2680–2685.
VulliamyTJMarroneAKnightSW. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood2006;107:2680–2685.
)| false
AlterBPBaerlocherGMSavageSA. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood2007;110:1439–1447.
AlterBPBaerlocherGMSavageSA. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood2007;110:1439–1447.
)| false
MichaudJWuFOsatoM. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood2002;99:1364–1372.
MichaudJWuFOsatoM. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood2002;99:1364–1372.
)| false
QuentinSCuccuiniWCeccaldiR. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood2011;117:e161–170.
QuentinSCuccuiniWCeccaldiR. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood2011;117:e161–170.
)| false
FadilahSACheongSKRoslanH. GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia2002;16:1563–1565.
FadilahSACheongSKRoslanH. GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia2002;16:1563–1565.
)| false
SteerEJCrossNC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol2002;107:113–122.
SteerEJCrossNC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol2002;107:113–122.
)| false
ApperleyJFGardembasMMeloJV. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med2002;347:481–487.
ApperleyJFGardembasMMeloJV. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med2002;347:481–487.
)| false
DavidMCrossNCBurgstallerS. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood2007;109:61–64.
DavidMCrossNCBurgstallerS. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood2007;109:61–64.
)| false
MagnussonMKMeadeKENakamuraR. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood2002;100:1088–1091.
MagnussonMKMeadeKENakamuraR. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood2002;100:1088–1091.
)| false
SteensmaDPDewaldGWLashoTL. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood2005;106:1207–209.
SteensmaDPDewaldGWLashoTL. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood2005;106:1207–209.
)| false
SzpurkaHTiuRMurugesanG. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood2006;108:2173–2181.
SzpurkaHTiuRMurugesanG. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood2006;108:2173–2181.
)| false
OgataKNakamuraKYokoseN. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood2002;100:3887–3896.
OgataKNakamuraKYokoseN. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood2002;100:3887–3896.
)| false
WellsDABeneschMLokenMR. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood2003;102:394–403.
WellsDABeneschMLokenMR. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood2003;102:394–403.
)| false
MalcovatiLGermingUKuendgenA. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol2007;25:3503–3510.
MalcovatiLGermingUKuendgenA. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol2007;25:3503–3510.
)| false
KaoJMMcMillanAGreenbergPL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol2008;83:765–770.
KaoJMMcMillanAGreenbergPL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol2008;83:765–770.
)| false
AlessandrinoEPDella PortaMGBacigalupoA. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood2008;112:895–902.
AlessandrinoEPDella PortaMGBacigalupoA. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood2008;112:895–902.
)| false
CermakJKacirkovaPMikulenkovaDMichalovaK. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res2009;33:1469–1474.
CermakJKacirkovaPMikulenkovaDMichalovaK. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res2009;33:1469–1474.
)| false
ParkMJKimHJKimSH. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol2008;81:364–373.
ParkMJKimHJKimSH. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol2008;81:364–373.
)| false
MalcovatiLDella PortaMGStruppC. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica2011;96:1433–1440.
MalcovatiLDella PortaMGStruppC. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica2011;96:1433–1440.
)| false
SchanzJTuchlerHSoleF. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol2012;30:820–829.
SchanzJTuchlerHSoleF. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol2012;30:820–829.
)| false
AdesLLamarqueMRaynaudS. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of mds patient treated with azacitidine (AZA): the Groupe Francophone Des Myelodysplasies (GFM) experience [abstract]. Blood2012;120:Abstract 422.
AdesLLamarqueMRaynaudS. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of mds patient treated with azacitidine (AZA): the Groupe Francophone Des Myelodysplasies (GFM) experience [abstract]. Blood2012;120:Abstract 422.
)| false
CermakJMikulenkovaDBrezinovaJMichalovaK. A reclassification of myelodysplastic syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall survival. A retrospective analysis of 49 patients [abstract]. Blood2012;120:Abstract 4957.
CermakJMikulenkovaDBrezinovaJMichalovaK. A reclassification of myelodysplastic syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall survival. A retrospective analysis of 49 patients [abstract]. Blood2012;120:Abstract 4957.
)| false
MessaEGioiaDEvangelistaA. High predictive value of the revised International Prognostic Scoring System (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry [abstract]. Blood2012;120:Abstract 1702.
MessaEGioiaDEvangelistaA. High predictive value of the revised International Prognostic Scoring System (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry [abstract]. Blood2012;120:Abstract 1702.
)| false
MishraAAliNHACorrales-YepezM. Validation of the revised International Prognostic Scoring System (R-IPSS) for patients with myelodysplastic syndromes: therapeutic implications [abstract]. Blood2012;120:Abstract 2816.
MishraAAliNHACorrales-YepezM. Validation of the revised International Prognostic Scoring System (R-IPSS) for patients with myelodysplastic syndromes: therapeutic implications [abstract]. Blood2012;120:Abstract 2816.
)| false
ValcarcelDSanzGOrtegaM. Identification of poor risk patients in low and intermediate-1 (Int-1) IPSS MDS with the new IPSSR index and comparison with other prognostic indexes. A study by the Spanish Group of MDS (GESMD) [abstract]. Blood2012;120:Abstract 702.
ValcarcelDSanzGOrtegaM. Identification of poor risk patients in low and intermediate-1 (Int-1) IPSS MDS with the new IPSSR index and comparison with other prognostic indexes. A study by the Spanish Group of MDS (GESMD) [abstract]. Blood2012;120:Abstract 702.
)| false
WarlickEDHirschBANguyenPL. Comparison of IPSS and IPSS-R scoring in a population based myelodysplastic syndromes (MDS) study [abstract]. Blood2012;120:Abstract 3841.
WarlickEDHirschBANguyenPL. Comparison of IPSS and IPSS-R scoring in a population based myelodysplastic syndromes (MDS) study [abstract]. Blood2012;120:Abstract 3841.
)| false
BejarRStevensonKECaugheyBA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol2012;30:3376–3382.
BejarRStevensonKECaugheyBA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol2012;30:3376–3382.
)| false
KomrokjiRSCorrales-YepezMAl AliNH. Validation of the lower risk MD Anderson prognostic scoring system for patients with myelodysplastic syndromes [abstract]. Blood2012;120:Abstract 3826.
KomrokjiRSCorrales-YepezMAl AliNH. Validation of the lower risk MD Anderson prognostic scoring system for patients with myelodysplastic syndromes [abstract]. Blood2012;120:Abstract 3826.
)| false
SekeresMAElsonPTiuRV. Validating the lower-risk MD Anderson prognostic scoring system (LR-PSS) and the revised International Prognostic Scoring System (IPSS-R) for patients with myelodysplastic syndromes [abstract]. Blood2011;118:Abstract 1720.
SekeresMAElsonPTiuRV. Validating the lower-risk MD Anderson prognostic scoring system (LR-PSS) and the revised International Prognostic Scoring System (IPSS-R) for patients with myelodysplastic syndromes [abstract]. Blood2011;118:Abstract 1720.
)| false
ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:3671–3674.
ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:3671–3674.
)| false
ChesonBDGreenbergPLBennettJM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood2006;108:419–425.
ChesonBDGreenbergPLBennettJM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood2006;108:419–425.
)| false
GreenbergPBaerMBennettJ. NCCN Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes. Version 12001. In: The Complete Library of NCCN Guidelines [CD-ROM]. Rockledge, PA: NCCN: 2001.
GreenbergPBaerMBennettJ. NCCN Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes. Version 1, 2001. In: The Complete Library of NCCN Guidelines [CD-ROM]. Rockledge, PA: NCCN: 2001.
)| false
GreenbergP. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. International Journal of Pediatric Hematology/Oncology1997;4:231–238.
GreenbergP. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. International Journal of Pediatric Hematology/Oncology1997;4:231–238.
)| false
Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:68–75.
Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:68–75.
)| false
KelaidiCBeyne-RauzyOBraunT. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol2013;92:621–631.
KelaidiCBeyne-RauzyOBraunT. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol2013;92:621–631.
)| false
KelaidiCParkSBrechignacS. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res2008;32:1049–1053.
KelaidiCParkSBrechignacS. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res2008;32:1049–1053.
)| false
ParkSGrabarSKelaidiC. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood2008;111:574–582.
ParkSGrabarSKelaidiC. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood2008;111:574–582.
)| false
TehranchiRFadeelBSchmidt-MendeJ. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res2005;11:6291–6299.
TehranchiRFadeelBSchmidt-MendeJ. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res2005;11:6291–6299.
)| false
HouwerzijlEJBlomNRvan der WantJJ. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood2005;105:3472–3479.
HouwerzijlEJBlomNRvan der WantJJ. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood2005;105:3472–3479.
)| false
TamuraHOgataKLuoS. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol1998;103:778–784.
TamuraHOgataKLuoS. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol1998;103:778–784.
)| false
GreenbergPLGarcia-ManeroGMooreM. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma2013;54:321–328.
GreenbergPLGarcia-ManeroGMooreM. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma2013;54:321–328.
)| false
KantarjianHFenauxPSekeresMA. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol2010;28:437–444.
KantarjianHFenauxPSekeresMA. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol2010;28:437–444.
)| false
KantarjianHMGilesFJGreenbergPL. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116:3163–3170.
KantarjianHMGilesFJGreenbergPL. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116:3163–3170.
)| false
SekeresMAKantarjianHFenauxP. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117:992–1000.
SekeresMAKantarjianHFenauxP. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117:992–1000.
)| false
WangESLyonsRMLarsonRA. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol2012;5:71.
WangESLyonsRMLarsonRA. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol2012;5:71.
)| false
MavroudiIPyrovolakiKPavlakiK. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res2011;35:323–328.
MavroudiIPyrovolakiKPavlakiK. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res2011;35:323–328.
)| false
WillBKawaharaMLucianoJP. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood2009;114:3899–3908.
WillBKawaharaMLucianoJP. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood2009;114:3899–3908.
)| false
HashimotoSTobaKFuseI. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol2000;64:225–230.
HashimotoSTobaKFuseI. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol2000;64:225–230.
)| false
LuoSSOgataKYokoseN. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells2000;18:112–119.
LuoSSOgataKYokoseN. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells2000;18:112–119.
)| false
FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223–232.
FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223–232.
)| false
KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:1794–1803.
KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:1794–1803.
)| false
LubbertMSuciuSBailaL. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol2011;29:1987–1996.
LubbertMSuciuSBailaL. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol2011;29:1987–1996.
)| false
SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol2002;20:2429–2440.
SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol2002;20:2429–2440.
)| false
SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:3895–3903.
SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:3895–3903.
)| false
SilvermanLRFenauxPMuftiGJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer2011;117:2697–2702.
SilvermanLRFenauxPMuftiGJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer2011;117:2697–2702.
)| false
LyonsRMCosgriffTMModiSS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol2009;27:1850–1856.
LyonsRMCosgriffTMModiSS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol2009;27:1850–1856.
)| false
MartinMGWalgrenRAProcknowE. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol2009;84:560–564.
MartinMGWalgrenRAProcknowE. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol2009;84:560–564.
)| false
LubbertMWijermansPKunzmannR. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol2001;114:349–357.
LubbertMWijermansPKunzmannR. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol2001;114:349–357.
)| false
WijermansPLubbertMVerhoefG. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol2000;18:956–962.
WijermansPLubbertMVerhoefG. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol2000;18:956–962.
)| false
SabaHRosenfeldCIssaJ. First report of the phase III north American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood2004;104:Abstract 67.
SabaHRosenfeldCIssaJ. First report of the phase III north American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood2004;104:Abstract 67.
)| false
van den BoschJLubbertMVerhoefGWijermansPW. The effects of 5-aza-2’-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res2004;28:785–790.
van den BoschJLubbertMVerhoefGWijermansPW. The effects of 5-aza-2’-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res2004;28:785–790.
)| false
SabaHLubbertMWijermansPW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2005;106:Abstract 2515.
SabaHLubbertMWijermansPW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2005;106:Abstract 2515.
)| false
KantarjianHMO’BrienSShanJ. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer2007;109:265–273.
KantarjianHMO’BrienSShanJ. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer2007;109:265–273.
)| false
KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:52–57.
KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:52–57.
)| false
DamajGDuhamelARobinM. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol2012;30:4533–4540.
DamajGDuhamelARobinM. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol2012;30:4533–4540.
)| false
FieldTPerkinsJHuangY. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant2010;45:255–260.
FieldTPerkinsJHuangY. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant2010;45:255–260.
)| false
GerdsATGooleyTAEsteyEH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant2012;18:1211–1218.
GerdsATGooleyTAEsteyEH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant2012;18:1211–1218.
)| false
LubbertMBertzHRuterB. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant2009;44:585–588.
LubbertMBertzHRuterB. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant2009;44:585–588.
)| false
DeegHJGotlibJBeckhamC. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia2002;16:162–164.
DeegHJGotlibJBeckhamC. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia2002;16:162–164.
)| false
DeegHJJiangPYHolmbergLA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res2004;28:1177–1180.
DeegHJJiangPYHolmbergLA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res2004;28:1177–1180.
)| false
RazaAMeyerPDuttD. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood2001;98:958–965.
RazaAMeyerPDuttD. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood2001;98:958–965.
)| false
SloandEMWuCOGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:2505–2511.
SloandEMWuCOGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:2505–2511.
)| false
ScheinbergPWuCOScheinbergP. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia [abstract]. Blood2010;116:Abstract LBA-4.
ScheinbergPWuCOScheinbergP. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia [abstract]. Blood2010;116:Abstract LBA-4.
)| false
StadlerMGermingUKlicheKO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia2004;18:460–465.
StadlerMGermingUKlicheKO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia2004;18:460–465.
)| false
FenauxPGiagounidisASelleslagD. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood2011;118:3765–3776.
FenauxPGiagounidisASelleslagD. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood2011;118:3765–3776.
)| false
KuendgenALausekerMListAF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia2013;27:1072–1079.
KuendgenALausekerMListAF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia2013;27:1072–1079.
)| false
RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:86–93.
RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:86–93.
)| false
EsteyEHThallPFCortesJE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood2001;98:3575–3583.
EsteyEHThallPFCortesJE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood2001;98:3575–3583.
)| false
SonneveldPvan DongenJJHagemeijerA. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia1993;7:963–969.
SonneveldPvan DongenJJHagemeijerA. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia1993;7:963–969.
)| false
AdvaniRSabaHITallmanMS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood1999;93:787–795.
AdvaniRSabaHITallmanMS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood1999;93:787–795.
)| false
WattelESolaryEHecquetB. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol1999;457:35–46.
WattelESolaryEHecquetB. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol1999;457:35–46.
)| false
GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:1078–1086.
GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:1078–1086.
)| false
De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151–155.
De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151–155.
)| false
DemuynckHVerhoefGEZacheeP. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant1996;17:745–751.
DemuynckHVerhoefGEZacheeP. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant1996;17:745–751.
)| false
JuradoMDeegHJStorerB. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant2002;8:161–169.
JuradoMDeegHJStorerB. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant2002;8:161–169.
)| false
NevillTJFungHCShepherdJD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood1998;92:1910–1917.
NevillTJFungHCShepherdJD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood1998;92:1910–1917.
)| false
ScottBLSandmaierBMStorerB. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia2006;20:128–135.
ScottBLSandmaierBMStorerB. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia2006;20:128–135.
)| false
WallenHGooleyTADeegHJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol2005;23:3439–3446.
WallenHGooleyTADeegHJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol2005;23:3439–3446.
)| false
Castro-MalaspinaHHarrisREGajewskiJ. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood2002;99:1943–1951.
Castro-MalaspinaHHarrisREGajewskiJ. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood2002;99:1943–1951.
)| false
DeegH. Optimization of transplant regimens for patients with myelodysplastic syndromes (MDS). In: Hematology 2005: American Society of Hematology Education Program Book: Washington, DC: American Society of Hematology; 2005;167–173.
DeegH. Optimization of transplant regimens for patients with myelodysplastic syndromes (MDS). In: Hematology 2005: American Society of Hematology Education Program Book: Washington, DC: American Society of Hematology; 2005;167–173.
)| false
DeegHJScottBLFangM. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood2012;120:1398–1408.
DeegHJScottBLFangM. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood2012;120:1398–1408.
)| false
de LimaMAnagnostopoulosAMunsellM. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood2004;104:865–872.
de LimaMAnagnostopoulosAMunsellM. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood2004;104:865–872.
)| false
McCluneBLWeisdorfDJPedersenTL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol2010;28:1878–1887.
McCluneBLWeisdorfDJPedersenTL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol2010;28:1878–1887.
)| false
SorrorMLSandmaierBMStorerBE. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol2007;25:4246–4254.
SorrorMLSandmaierBMStorerBE. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol2007;25:4246–4254.
)| false
De WitteTSuciuSVerhoefG. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood2001;98:2326–2331.
De WitteTSuciuSVerhoefG. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood2001;98:2326–2331.
)| false
AlyeaEPKimHTHoV. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood2005;105:1810–1814.
AlyeaEPKimHTHoV. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood2005;105:1810–1814.
)| false
CutlerCSLeeSJGreenbergP. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood2004;104:579–585.
CutlerCSLeeSJGreenbergP. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood2004;104:579–585.
)| false
LaportGGSandmaierBMStorerBE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant2008;14:246–255.
LaportGGSandmaierBMStorerBE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant2008;14:246–255.
)| false
McCluneBWeisdorfDDiPersioJ. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR) [abstract]. Blood2008;112:Abstract 346.
McCluneBWeisdorfDDiPersioJ. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR) [abstract]. Blood2008;112:Abstract 346.
)| false
OlianskyDMAntinJHBennettJM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant2009;15:137–172.
OlianskyDMAntinJHBennettJM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant2009;15:137–172.
)| false
BeranMShenYKantarjianH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer2001;92:1999–2015.
BeranMShenYKantarjianH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer2001;92:1999–2015.
)| false
WijermansPSuciuSBailaL. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groups [abstract]. Blood2008;112:Abstract 226.
WijermansPSuciuSBailaL. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groups [abstract]. Blood2008;112:Abstract 226.
)| false
Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:67–71.
Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:67–71.
)| false
NegrinRSSteinRDohertyK. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood1996;87:4076–4081.
NegrinRSSteinRDohertyK. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood1996;87:4076–4081.
)| false
CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321–327.
CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321–327.
)| false
Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344–351.
Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344–351.
)| false
SpiritiMALatagliataRNiscolaP. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol2005;84:167–176.
SpiritiMALatagliataRNiscolaP. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol2005;84:167–176.
)| false
Hellstrom-LindbergEGulbrandsenNLindbergG. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol2003;120:1037–1046.
Hellstrom-LindbergEGulbrandsenNLindbergG. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol2003;120:1037–1046.
)| false
MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513–519.
MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513–519.
)| false
MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204–209.
MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204–209.
)| false
GiraldoPNomdedeuBLoscertalesJ. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer2006;107:2807–2816.
GiraldoPNomdedeuBLoscertalesJ. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer2006;107:2807–2816.
)| false
StasiRAbruzzeseELanzettaG. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol2005;16:1921–1927.
StasiRAbruzzeseELanzettaG. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol2005;16:1921–1927.
)| false
GreenbergPLSunZMillerKB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood2009;114:2392–2400.
GreenbergPLSunZMillerKB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood2009;114:2392–2400.
)| false
KornblithABHerndonJEIISilvermanLR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol2002;20:2441–2452.
KornblithABHerndonJEIISilvermanLR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol2002;20:2441–2452.
)| false
ThomasM. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: GreenbergPL ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263–295.
ThomasM. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: GreenbergPL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263–295.
)| false
